April, 2016:
NBS-C BioScience signs a CRO Frame Contract with Mosaic Biomedicals SL, Barcelona, Spain, to accompany development of a novel therapeutic monoclonal antibody through all pre-clinical stages, establish a GxP validated SPR based identity / potency assay for clinical sample measurement and batch release during clinical development phases.
June, 2015:
Publication of patent application PCT/EP2014/077937, disclosing a new chemical compound for treatment of neuropathic pain and other disorders, displaying a novel mode of action discovered in collaboration of NBS-C BioScience with NovAssay SA, Switzerland
May, 2014:
Key data generated at NBS-C BioScience during a research cooperation with the Institute of Molecular Biotechnology, Vienna (IMBA) are published in Nature 511, 104-107
March, 2013:
NBS-C BioScience and Fresenius Kabi, Germany, sign a five year CRO frame contract
February 2013:
NBS-C BioScience and Harvard Medical School, Children‘s Hospital, initiate collaboration
January, 2013:
The service level contract with Baxter Innovations is prolonged for another two year period
November 2011:
NBS-C BioScience signs a two year service level contract with Baxter Innovations Austria